RTP Mobile Logo
Oncology Today: Gastrointestinal Cancers Edition 2019 — Hepatocellular Carcinoma (Video Program)
Released February 2019

Featuring a roundtable discussion with Drs Anthony El-Khoueiry and R Kate Kelley. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal cancers.

    OVERVIEW OF ACTIVITY
    Hepatocellular carcinoma (HCC), the most common form of liver cancer, is the fourth leading cause of cancer-related death worldwide. A rising incidence, multiple etiologies, genetic heterogeneity and concurrent chronic liver disease make the selection of treatment for HCC challenging, and the disease is often diagnosed in the advanced stage, at which it is associated with poor prognosis. Recent breakthroughs in understanding the etiology and pathogenesis have led to the advent of new treatment modalities and investigational therapies. In order to offer optimal patient care, the practicing oncologist must be well informed of these advances.

    To bridge the gap between research and patient care, this issue of Oncology Today focusing on HCC features a discussion with 2 leading gastrointestinal oncology investigators. By providing access to the latest research developments and expert perspectives on the disease, this CME activity assists medical oncologists and select gastroenterology specialists in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Consider patient age, performance status, liver function and other clinical and logistical factors in the up-front and subsequent management of unresectable or metastatic HCC.
    • Appraise recent Phase III data with lenvatinib, and consider its clinical role in the care of patients with previously untreated unresectable HCC.
    • Appreciate the recent FDA approval of cabozantinib for patients who have previously received sorafenib, and consider how this agent can be optimally integrated into therapy for these individuals.
    • Understand the biologic rationale for immune checkpoint inhibition in the treatment of HCC, and recall available clinical data with approved and investigational checkpoint inhibitors.
    • Recognize immune-related adverse events and other common side effects associated with approved and developmental immune checkpoint inhibitors, and offer supportive management strategies to minimize and manage these toxicities.
    • Evaluate the latest Phase III data with ramucirumab for patients with advanced HCC and elevated alpha-fetoprotein who previously received sorafenib.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of each of these CME activities, which includes participation in the evaluation component, enables the participant to earn up to 1.5 (audio) and 1.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THESE CME ACTIVITIES
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OncologyTodayGI19/HCC/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/OncologyTodayGI19/HCC/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OncologyTodayGI19/HCC/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/OncologyTodayGI19/HCC.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Anthony El-Khoueiry, MD
    Associate Professor of Clinical Medicine
    Medical Director of Clinical Investigations Support Office
    Phase I Program Director
    USC Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, CytomX Therapeutics, Eisai Inc, EMD Serono Inc, Exelixis Inc, Merck, Pieris Pharmaceuticals Inc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP.

    R Kate Kelley, MD
    Associate Professor of Clinical Medicine
    Department of Medicine (Hematology/Oncology)
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Advisory Committee: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company; Contracted Research: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Lilly, Merck, Novartis, QED Therapeutics, Taiho Oncology Inc; Data and Safety Monitoring Board: Genentech/Roche Laboratories Inc; Steering Committee and Publications Committee: TARGET PharmaSolutions Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: February 2019
    Expiration date: February 2020

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

View video
(WIFI is recommended for best performance):